Arcutis Biotherapeutics (ARQT) Short Interest Ratio & Short Volume $9.26 -0.67 (-6.75%) (As of 11/15/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Arcutis Biotherapeutics Short Interest DataArcutis Biotherapeutics (ARQT) has a short interest of 27.76 million shares. This marks a -1.07% decrease in short interest from the previous month. The short interest ratio (days to cover) is 13.1, indicating that it would take 13.1 days of the average trading volume of 3.24 million shares to cover all short positions.Current Short Interest27,760,000 sharesPrevious Short Interest28,060,000 sharesChange Vs. Previous Month-1.07%Dollar Volume Sold Short$230.69 millionShort Interest Ratio13.1 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares117,040,000 sharesPercentage of Shares Shorted23.72%Today's Trading Volume3,018,887 sharesAverage Trading Volume3,244,752 sharesToday's Volume Vs. Average93% Short Selling Arcutis Biotherapeutics? Sign up to receive the latest short interest report for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartARQT Short Interest Over TimeARQT Days to Cover Over TimeARQT Percentage of Float Shorted Over Time Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Arcutis Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/202427,760,000 shares $230.69 million -1.1%N/A13.1 $8.31 10/15/202428,060,000 shares $262.36 million +3.4%N/A13.7 $9.35 9/30/202427,130,000 shares $252.31 million +9.1%N/A12.7 $9.30 9/15/202424,860,000 shares $265.01 million +0.7%N/A10.5 $10.66 8/31/202424,680,000 shares $268.52 million +3.7%N/A9.9 $10.88 8/15/202423,800,000 shares $202.30 million +8.4%N/A9 $8.50 Get the Latest News and Ratings for ARQT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/202421,950,000 shares $221.04 million -3.1%N/A7.8 $10.07 7/15/202422,660,000 shares $244.05 million +6.2%N/A8 $10.77 6/30/202421,340,000 shares $198.46 million -18.0%N/A7 $9.30 6/15/202426,020,000 shares $224.55 million +5.6%N/A8.7 $8.63 5/31/202424,640,000 shares $205.99 million +11.1%N/A7.7 $8.36 5/15/202422,170,000 shares $204.85 million +2.2%N/A6 $9.24 4/30/202421,690,000 shares $180.46 million +10.3%N/A5.7 $8.32 4/15/202419,660,000 shares $198.37 million +2.1%N/A4.3 $10.09 3/31/202419,260,000 shares $190.87 million +28.5%N/A4 $9.91 3/15/202414,990,000 shares $159.79 million -5.0%N/A2.8 $10.66 2/29/202415,780,000 shares $162.22 million -6.9%N/A2.6 $10.28 2/15/202416,940,000 shares $135.01 million +1.0%N/A2.9 $7.97 1/31/202416,780,000 shares $98.50 million -19.4%N/A3.1 $5.87 1/15/202420,830,000 shares $75.82 million +3.2%N/A4.1 $3.64 12/31/202320,180,000 shares $65.18 million +3.7%N/A4.2 $3.23 12/15/202319,460,000 shares $47.48 million -6.9%N/A4.8 $2.44 11/30/202320,900,000 shares $38.46 million +19.4%N/A8.2 $1.84 11/15/202317,510,000 shares $36.42 million +2.6%N/A8 $2.08 10/31/202317,070,000 shares $38.41 million +21.4%N/A8.5 $2.25 10/15/202314,060,000 shares $54.55 million +8.3%N/A8.7 $3.88 9/30/202312,980,000 shares $68.92 million -2.3%29.0%12.1 $5.31 9/15/202313,280,000 shares $90.44 million +6.4%29.7%13.1 $6.81 8/31/202312,480,000 shares $106.58 million -19.2%27.9%11.3 $8.54 8/15/202315,450,000 shares $130.86 million +1.6%34.5%12.8 $8.47 7/31/202315,210,000 shares $165.94 million +3.1%33.9%12.3 $10.91 7/15/202314,760,000 shares $139.33 million +0.2%32.8%11.9 $9.44 6/30/202314,730,000 shares $140.38 million +12.5%32.8%11.3 $9.53 6/15/202313,090,000 shares $133.78 million +0.4%29.1%10 $10.22 5/31/202313,040,000 shares $97.93 million -13.1%29.1%10.3 $7.51 5/15/202315,010,000 shares $154.60 million -2.5%33.7%13.1 $10.30 4/30/202315,390,000 shares $213.00 million +0.3%35.2%15.6 $13.84 4/15/202315,350,000 shares $213.21 million +1.5%35.1%15.5 $13.89 3/31/202315,120,000 shares $166.32 million +10.0%34.5%15.4 $11.00 3/15/202313,750,000 shares $152.76 million +11.1%31.4%14.9 $11.11Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now 2/28/202312,380,000 shares $200.31 million +4.2%28.2%15 $16.18 2/15/202311,880,000 shares $203.62 million +10.1%27.2%15 $17.14 1/31/202310,790,000 shares $178.79 million +0.5%25.0%13 $16.57 1/15/202310,740,000 shares $151.65 million +0.9%24.9%13.1 $14.12 12/30/202210,650,000 shares $157.62 million +6.8%24.7%13.9 $14.80 12/15/20229,970,000 shares $164.41 million +5.1%23.1%12.7 $16.49 11/30/20229,490,000 shares $163.51 million +17.9%22.0%12.6 $17.23 11/15/20228,050,000 shares $156.49 million +0.1%18.7%10.8 $19.44 10/31/20228,040,000 shares $142.15 million +17.4%19.2%12.1 $17.68 10/15/20226,850,000 shares $127.68 million +14.4%16.4%9.1 $18.64 9/30/20225,990,000 shares $114.47 million +15.2%14.3%8.6 $19.11 9/15/20225,200,000 shares $97.19 million +1.6%12.5%7.7 $18.69 8/31/20225,120,000 shares $137.98 million -1.7%12.4%8.4 $26.95 8/15/20225,210,000 shares $128.79 million +13.8%12.9%9 $24.72 7/31/20224,580,000 shares $111.11 million +16.8%12.6%8.2 $24.26 7/15/20223,920,000 shares $94.86 million +12.3%12.6%9.5 $24.20 6/30/20223,490,000 shares $74.37 million +5.8%11.3%8.6 $21.31 6/15/20223,300,000 shares $67.82 million +6.8%10.5%8.6 $20.55 5/31/20223,090,000 shares $64.52 million +6.2%9.8%8.8 $20.88 5/15/20222,910,000 shares $52.18 million -1.4%9.5%9.8 $17.93 4/30/20222,950,000 shares $59.56 million +3.2%9.6%10.5 $20.19 4/15/20222,860,000 shares $60.15 million -15.4%9.5%10.3 $21.03 3/31/20223,380,000 shares $65.10 million -9.1%12.1%12.5 $19.26 3/15/20223,720,000 shares $59.45 million +15.9%13.3%15.9 $15.98 2/28/20223,210,000 shares $57.14 million +3.2%11.4%15.8 $17.80 2/15/20223,110,000 shares $51.32 million +6.9%11.1%14.4 $16.50 1/31/20222,910,000 shares $43.97 million +26.0%10.6%14.5 $15.11 1/15/20222,310,000 shares $40.22 million +9.0%8.4%12.4 $17.41 12/31/20212,120,000 shares $43.97 million +7.1%7.7%12.7 $20.74 12/15/20211,980,000 shares $31.68 million No Change7.2%11.7 $16.00 11/30/20211,980,000 shares $32.81 million -1.0%7.2%12.1 $16.57 11/15/20212,000,000 shares $40.50 million +0.5%7.3%13.3 $20.25 10/29/20211,990,000 shares $42.15 million +1.0%7.2%14 $21.18 10/15/20211,970,000 shares $43.89 million -0.5%7.2%12.7 $22.28 9/30/20211,980,000 shares $47.30 million -4.4%7.2%12.1 $23.89 9/15/20212,070,000 shares $45.08 million -5.5%7.5%11.6 $21.78 8/31/20212,190,000 shares $46.36 million -4.0%8.0%12.6 $21.17 8/13/20212,280,000 shares $46.69 million -1.3%8.3%13.2 $20.48 7/30/20212,310,000 shares $53.89 million +2.2%8.5%11.3 $23.33 7/15/20212,260,000 shares $56.23 million No Change6.8%9.6 $24.88 6/30/20212,260,000 shares $61.68 million -0.9%6.8%9.5 $27.29 6/15/20212,280,000 shares $65.00 million -1.3%6.9%10.4 $28.51 5/28/20212,310,000 shares $60.87 million -0.9%6.9%10.4 $26.35 5/14/20212,330,000 shares $59.53 million +17.7%7.0%9.9 $25.55 4/30/20211,980,000 shares $60.49 million -0.5%6.4%8.4 $30.55 4/15/20211,990,000 shares $55.90 million +7.0%6.5%7.7 $28.09 3/31/20211,860,000 shares $50.07 million +19.2%6.0%7.2 $26.92 3/15/20211,560,000 shares $50.78 million +9.9%5.1%5.6 $32.55 2/26/20211,420,000 shares $48.62 million +0.7%4.6%5.1 $34.24 2/12/20211,410,000 shares $49.08 million -6.6%4.7%5.2 $34.81Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now 1/29/20211,510,000 shares $39.35 million -8.5%5.4%5.8 $26.06 1/15/20211,650,000 shares $47.01 million No Change6.6%8.4 $28.49 ARQT Short Interest - Frequently Asked Questions What is Arcutis Biotherapeutics' current short interest? Short interest is the volume of Arcutis Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 27,760,000 shares of ARQT short. Learn More on Arcutis Biotherapeutics' current short interest. What is a good short interest ratio for Arcutis Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ARQT shares currently have a short interest ratio of 13.0. Learn More on Arcutis Biotherapeutics's short interest ratio. Is Arcutis Biotherapeutics' short interest increasing or decreasing? Arcutis Biotherapeutics saw a decrease in short interest in October. As of October 31st, there was short interest totaling 27,760,000 shares, a decrease of 1.1% from the previous total of 28,060,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Arcutis Biotherapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Arcutis Biotherapeutics: Innoviva, Inc. (19.02%), Phathom Pharmaceuticals, Inc. (25.52%), Kiniksa Pharmaceuticals, Ltd. (5.83%), Ocular Therapeutix, Inc. (8.13%), ORIC Pharmaceuticals, Inc. (16.51%), Supernus Pharmaceuticals, Inc. (12.86%), Nkarta, Inc. (13.56%), Karyopharm Therapeutics Inc. (14.12%), BioXcel Therapeutics, Inc. (0.85%), Biohaven Ltd. (9.05%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Arcutis Biotherapeutics stock? Short selling ARQT is an investing strategy that aims to generate trading profit from Arcutis Biotherapeutics as its price is falling. ARQT shares are trading down $0.67 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arcutis Biotherapeutics? A short squeeze for Arcutis Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ARQT, which in turn drives the price of the stock up even further. How often is Arcutis Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ARQT, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies Innoviva Short Squeeze Phathom Pharmaceuticals Short Squeeze Kiniksa Pharmaceuticals Short Squeeze Ocular Therapeutix Short Squeeze ORIC Pharmaceuticals Short Squeeze Supernus Pharmaceuticals Short Squeeze Nkarta Short Squeeze Karyopharm Therapeutics Short Squeeze BioXcel Therapeutics Short Squeeze Biohaven Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ARQT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
